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S364 Poster Session IIlymphoma.Within the 11-mere, the peptide with the highest affinity
to an MCH allele was a 9-mere and tetrameres with the MCH allele
A2402 and the 9-mere positively stained expanded T-cells. The tet-
ramere positive T-cells were found to be CD107a-positive after
stimulation with dendritic cells pulsed with the peptide. T-cells spe-
cific for that HY minor were found after expansion in two of four
A2402 positive patient/donor pairs with female donor and male pa-
tient.
Conclusion: A new HY minor has been identified using a high-
throughput methodology suitable for identifying more HY minors
and possibly also autosomally expressed minor histocompatibility
antigens.433
IS LIVER BIOPSY NECESSARY IN THE MANAGEMENT OF ALLOGENEIC
STEM CELL TRANSPLANT RECIPIENTS WITH GRAFT-VERSUS-HOST DIS-
EASE?
Ye, J.C.1, Hukku, S.2, Bentley, G.2, Lebeis, T.1, Ratanatharathorn, V.3,
Ayash, L.3, Abidi, M.H.3, Al-Kadhimi, Z.3, Deol, A.3, Mellert, K.4,
Uberti, J.P.3 1Wayne State University, Detroit, MI; 2Wayne State Uni-
versity, Detroit, MI; 3Wayne State University, Detroit, MI; 4Karmanos
Cancer Institute, Detroit, MI
Background: Liver function abnormalities are common after hema-
topoietic stem cell transplantation (HSCT) and liver biopsy is often
used to direct treatment. We reviewed 117 consecutive liver biopsies
during the last 8 years at our institution.
Materials and Methods: From 2003 to 2010, 117 liver biopsies were
performed on patients who had undergoneHSCT for hematological
malignancies and presented with liver dysfunction. All slides were
evaluated for features of GVHD by cholestasis, fibrosis, lobular in-
flammation, iron deposition and were graded from 0 to 3 (0 5
none, 1 5 mild, 2 5 moderate and 3 5 severe).
Results: The median age of the patients was 49 (range 14-66). Fifty
seven (49%) patients underwent related donor (RD) and 60 (51%)
unrelated donor (URD) transplantations. Preparative regimens
were applied based on their disease; GVHD prophylaxis was tacroli-
mus and mycophenolic acid in 105 (88%) patients; tacrolimus, siro-
limus and thymoglobulin in 6 (5%), and other regiments in 6 (5%).
Fifty nine patients were alive with a median follow up for the surviv-
ing patients of 4.2 years (range 0.9-9.3 years). Kaplan-Meier estimate
of overall survival at 6 years was 43% +/- 5%. Liver biopsies were
preformed at a median of 173 days post-transplant (range 22-1366
days). At the time of the liver biopsy, the median AST was 168 IU/
L (range 18-1425 IU/L), ALT 250 IU/L (range 38-1495 IU/L), total
bilirubin 1.1 mg/dL (range 0.1-26.8 mg/dL) and alkaline phospha-
tase 278 IU/L (range 69-1547 IU/L). On biopsy there were 107
(91%) patients with histological features of GVHD: mild 29
(27%), moderate 56 (52%) or severe 22 (21%). Iron deposition stud-
ies showed 5 (4%) patients without iron deposition, 23 (20%) pa-
tients grade 1, 38 (32%) patients grade 2, and 51 (44%) patients
grade 3. In multivariate analysis of relevant prognostic factors in-
cluding age, donor, total bilirubin, ALT and histological grade of
cholestasis, only total bilirubin of\5 1.5 IU/L predicted favorable
survival (hazard ratio 5 0.34; 95% CI 0.19 - 0.63, p 5 0.001).
Conclusion: Liver biopsy confirmed the presence of GVHD in most
patients. The histological features of GVHDand iron deposition did
not adversely influence the survival. The most significant predictor
of survival was the presence of cholestasis on biopsy and the elevation
of total bilirubin of.1.5 mg/dL. Our data indicated limited value of
liver biopsy in management of patients with liver dysfunction after
allogeneic stem cell transplantation.434
GENETIC VARIATIONS IN THE ACTIVATION AND EFFECTOR PATHWAYS
OF CYTOTOXIC T LYMPHOCYTES MODULATE ALLOIMMUNE REACTIV-
ITIES AND HAVE PROGNOSTIC SIGNIFICANCE FOLLOWING ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION
Xiao, H.1,2, Luo, Y.1, Shi, J.1, Tan, Y.1, He, J.1, Xie, W.1, Ye, X.1,
Cai, Z.1, Lin, M.1, Huang, H.1 1The First Affiliated Hospital, ZhejiangUniversity School of Medicine, Hangzhou, Zhejiang, China; 2Guangzhou
Liuhuaqiao Hospital, Guangzhou, Guangdong, China
Objectives: Donor T lymphocytes play a critical role in alloim-
mune reactivities after allogeneic hematopoietic stem cell trans-
plantation (allo-HSCT). CD28, inducible co-stimulator (ICOS)
and cytotoxic T-lymphocyte antigen 4 (CTLA-4) belong to the
same family of T-cell costimulatory molecules. After activation,
three effector pathways have been described for T-cell cytotoxic-
ity: granzyme B/perforin, Fas/Fas ligand (FasL) and secreted
molecules such as TNF-alpha. Near recently, several important
polymorphisms have been identified in those genes and reported
to be associated with the risk of autoimmune diseases, malignan-
cies and allograft rejection in solid organ transplantation patients.
However, such information is less available in allo-HSCT. In the
present study, we first investigated the influence of those genes
polymorphic features on the abilities of T-cell alloimmune re-
sponses in allo-HSCT setting.
Methods: We analyzed 10 single nucleotide polymorphisms
(SNPs) in the CD28, ICOS, CTLA-4, Granzyme B, Fas and
FasL genes in 138 pairs of recipients and their unrelated donors
(URDs) and 102 pairs of recipients and their HLA-identical sib-
ling donors.
Results: (1) We found two SNPs in donors influenced the risk of
aGVHD. The association was particularly strong in the URD trans-
plantation cohort. Unrelated donor with Granzyme B +55 mutated
genotype (AA) was an independent risk factor for grades II-IV
aGVHD (P5 0.024, RR5 1.811, 95%CI, 1.080-3.038). While un-
related donor with CTLA-4 CT60 mutated genotype (AA) was pro-
tective (P 5 0.025, RR 5 3.806, 95%CI, 1.187-12.204). (2)
However, donor with CTLA-4 CT60 AA genotype was a risk of
early CMV infection (P \ 0.0001, RR 5 0.383, 95%CI, 0.243-
0.605) and relapse after allo-HSCT in AML patients (P 5 0.047,
RR 5 2.792 95%CI, 1.013-7.696). Furthermore, AML patients
with Fas -670 homogeneous mutated allele (TT genotype) also
had a higher risk of relapse (P 5 0.003, RR 5 3.823 95%CI,
1.566-9.337). (3) The presence of those susceptible alleles in donor
and/ or recipient (patients receiving CTLA-4 CT60 AA donor, pa-
tients receiving GranzymeB +55 AA donor, AML patients with Fas
-670 TT genotype or with all) resulted in a reduced overall survival
compared with those with wild-type genotypes (54.9% vs 69.5%,
P 5 0.029).
Conclusions:The results of this study highlight the important effect
of genetic variations in T-cell activation and effector pathways from
the donors and recipients on the outcomes of allo-HSCT.435
SEVERE CHRONIC GRAFT-VERSUS-HOST DISEASE IS ASSOCIATED WITH
IMPAIRED THYMOPOIESIS AND PERIPHERAL LYMPHOCYTE EXPANSION
Buxbaum, N.P.1, Williams, K.M.1, Amarnath, S.1, Treadwell, S.1,
Eckhaus, M.2, Gress, R.E.1 1NIH, NCI, Bethesda, MD; 2NIH, NCI, Be-
thesda, MD
Allogeneic hematopoietic stem cell transplantation (AHSCT) is
a curative therapy for hematologic malignancies. Chronic GVHD
(cGVHD) is a significant barrier to successful AHSCT. Although
T cells have been implicated in cGVHD pathobiology, the role
of the thymus in this process has yet to be clearly defined. We
characterized thymus and spleen T cell subsets in a murine
model of cGVHD (B10.D2/BALB/c) to investigate the role
of the thymus in this process. Once cGVHD was well-estab-
lished, 4-6 weeks post AHSCT, total thymocyte numbers in
mice with cGVHD were more than 20-fold depleted compared
to syngeneic controls. Furthermore, the double positive thymo-
cyte cell population (CD4+ CD8+) was most markedly reduced,
with a 90-fold reduction in numbers compared to syngeneic con-
trols. Despite evidence of thymic atrophy and diminished thymo-
poiesis, thymic CD4+ single positive cells were decreased less
proportionally (13-fold). Congenic AHSCT demonstrated that
this CD4+ population was comprised of donor peripherally de-
rived CD44hi memory T cells, representing an allogeneic infil-
trate. Further evidence of diminished thymic output was found
in the periphery. Live splenocytes were 3-fold depleted in
Poster Session II S365animals with cGVHD, with the CD4+ population having a 13-
fold reduction compared to syngeneic controls. By cell surface
phenotype, the recent thymic emigrant (RTE) CD4 proportion
(CD4+ CD44lo CCR7+ CD69-) was most severely affected, dem-
onstrating a 100-fold reduction. The spleens of affected animals
were enriched for memory T cells, particularly T effector mem-
ory (CD4+ or CD8+ CD44 high CCR7-). Furthermore, the ef-
fector memory T splenocytes of mice with cGHVD were more
likely to have an activated phenotype as evidenced by CD69 ex-
pression. Congenic AHSCT confirmed that the splenic CD4+
compartment was donor-derived. The total number of splenic
T regulatory cells (CD4hi Foxp3+ CD25+) was diminished in an-
imals with cGVHD; however, the proportion of this subset was
increased in the cGVHD mice. The T reg compartment was
also donor peripherally derived. These data show that cGVHD
is associated with impaired thymopoiesis. The relative CD4 lym-
phopenia and diminished RTE numbers likely stem from im-
paired thymic output and are associated with donor-derived
peripherally expanded CD4+ cell predominance.436
CD28-DIRECTED T CELL COSTIMULATION BLOCKADE WITH ABATACEPT
TO PREVENT GVHD DURING HIGH-RISK UNRELATED HSCT: A FIRST-IN-
DISEASE TRIAL
Kean, L.S.1, Langston, A.2, Qayed, M.1, Khoury, J.2, Tiwari, D.1,
Couture, C.1, Renfroe, H.2, Sen, S.1, Robertson, J.1, Waller, E.K.2,
Horan, J.1 1Emory University School of Medicine, Atlanta, GA; 2Emory
University School of Medicine, Atlanta, GA
We describe a first-in-disease trial of CD28-directed costimu-
lation blockade to prevent GvHD after URD HSCT in patients
.12y with advanced heme malignancies (Clinical Trials.Org
#NCT01012492). In this trial, 10 mg/kg abatacept is adminis-
tered on d -1, +5, +14, and +28 in addition to standard GvHD
prophylaxis (cyclosporine + methotrexate). 10 of 11 planned pa-
tients have enrolled, of which 8 are evaluable for engraftment
and toxicity, and 5 are evaluable for the primary immunologic
outcome of the study: the incidence of steroid-requiring GvHD
at d+100 post-transplant. The median patient age is 46 y (17-
74 y). 5 transplants were 7/8 HLA matched and 3 were 8/8
matched. 7 of the 8 patients are currently alive and in remission.
1 patient relapsed at d+98 (and died on d+121 with refractory
AML). The other 7 patients are surviving without relapse with
a follow-up of 57-377d.
All 8 patients received the 4 scheduled abatacept doses, without in-
fusional side-effects. All patients achieved neutrophil engraftment
(median d+19) and donor engraftment (100% CD33 chimerism at
d+30). Of the five post- d+100 patients, all demonstrated rapid lym-
phocyte engraftment (mean ALC.500 cells/mL by d+21). At d+100,
their mean CD3+, CD8+ and CD4+ T cell counts were 673 +/- 251,
384 +/- 148, and 229 +/- 119 cells/mL, respectively. T cell reconsti-
tution was accompanied by a shift toward a CCR7-/CD45RA- effec-
tor memory (Tem) phenotype, with CD4+ Tem increasing from 22
+/- 6% pre-transplant to 46 +/- 7%, and CD8+Tem increasing from
15 +/- 4% pre-transplant to 32 +/- 7%, both with a reciprocal de-
crease in Tnaive cells.
At the d+100 primary end-point, only 1 of the 5 evaluable patients
on the abatacept trial developed steroid-requiring GvHD. 3 addi-
tional patients are \100 days post-transplant (between d+57-64),
and none has developed GvHD. In striking contrast, in a contempo-
raneously transplanted cohort of 5 patients enrolled on an immune
monitoring protocol (and who had the same disease indications
and transplant preparative regimens, but who received standard
GvHD prophylaxis), 4 of 5 of these patients developed steroid-re-
quiring GvHD before d+100. 2 patients required salvage therapy
and one patient died from GvHD.
These preliminary data suggest that abatacept can be safely added
to cyclosporine and methotrexate for GVHD prophylaxis during
URD HSCT, with encouraging rates of GVHD at the d+100 pri-
mary endpoint. As such, they support the conduct of a larger, ran-
domized phase 2 study.437
NILOTINIB (TASIGNA) THERAPY POST ALLOGENEIC STEM CELL TRANS-
PLANTATION (ALLoSCT) FOR ADVANCED (.CP1) CHRONIC MYELOID
LEUKEMIA (CML) AND PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
Nagler, A., Volchek, Y., Varda-Bloom, N., Somech, R., Yerushalmi, R.,
Shimoni, A. Chaim Sheba Medical Center, Ramat Gan, Israel
Relapse rate post alloSCT in advanced CML (.CP1) and in Ph+
ALL is high. We assessed (study CAN107AIL03T) whether Niloti-
nib administration post alloSCT intensifies remission and reduce re-
lapses. 24 pts (M-13, F-11), age 36 years (range, 18-58) participated
in the study. 17 pts were with advanced CML (BC-10, AP-7) and 7
with Ph+ ALL. 22/24 pts underwent alloSCT (2 are pending) from
an HLA-matched sibling (n5 11), matched unrelated (n 5 8) or al-
ternative donor (CB-2, Haplo-1). All, but one, had myeloablative
conditioning (Bu/Cy or Flu/Bu-14, TBI/Cy-7). GVHD prophylaxis
includedCSA andmethotrexate orMMF. 21/22 pts engrafted inme-
dian day+13 (range, 9-38) with 100% donor chimerism. TRT in-
cluded mucositis in all pts, encephalitis-2, pericarditis-1, VOD-1
and infection-3. 3 pts died very early post transplant from sepsis
and multi organ failure. Acute GVHD $ Gr II was observed in 10
pts (III-IV in 5). cGVHD was observed in 15 pts (extensive – 9).
16/22 transplanted pts received Nilotinib (200mg x 2/d – 10,
300mg x 2/d – 6) starting at median day +38 (range, 30-158) post al-
loSCT. 6 pts did not receive Nilotinib post alloSCT due to early
death -3, progressive disease -1, severe pancytopenia -1, refusal -1.
Nilotinib administration was delayed or dose reduced/stopped in 9
and 7 pts, respectively due to toxicities. All, but 2 pts achieved
MMR post alloSCT and 6 of them (CML) converted to CMR fol-
lowing Nilotinib therapy. Kinas mutation (G205E and F359V)
were detected only in 1 pt with disease progression. With a median
follow up of 16.5 mo (range, 2.5-38) 12 pts are alive while 12 died
(Infection -5, GVHD -3, TTP-1, disease progression -3). In 2 pts
disease progressed but responded to further therapy. All 6 pts that
did not receive Nilotinib died (early death post allo-SCT -3, disease
progression -1, GVHD Gr IV -2). Immunological evaluation post
Nilotinib administration disclosed no significant change in T, B
andNK cell numbers and T cell mitogenic response. Thymic output
(TREC) and receptor repertoire (Spectrotyping) analysis indicates
continuous thymopoiesis in 8/13 evaluated pts. NK cytotoxic activity
against K562 increased in 9/15 evaluated pts. In conclusion, post al-
loSCT Nilotinib maintenance therapy in extremely high risk pts
with advanced CML and Ph+ ALL may prevent relapse and disease
progressionand should be recommend as 1) pts achievedMMR and 6
converted to CMR with Nilotinib therapy and 2) only 5/16 pts that
received Nilotinib post alloSCT progressed.438
ALEMTUZUMAB FOR STEROID REFRACTORY ACUTE GRAFT VERSUS HOST
DISEASE IN PEDIATRIC PATIENTS: A RETROSPECTIVE REVIEW OF 12 PA-
TIENTS REVEALS A RESPONSE RATE OF 83%
Khandelwal, P., Filipovich, A.H., Mehta, P., Jodele, S., Grimley, M.S.,
Myers, K., Jordan, M.B., Kumar, A., Bleesing, J.J., Davies, S.M.,
Marsh, R.A. Cincinnati Children’s Hospital, Cincinnati, OH
High dose steroids are themainstay of treatment of acute graft ver-
sus host disease (GVHD) with a response rate of 30-70%. A clear
second line agent for steroid refractory graft versus host disease
has not been established and it remains a significant cause of morbid-
ity and mortality in allogeneic hematopoietic cell transplant (HCT)
recipients. In order to estimate the effectiveness of alemtuzumab for
the treatment of steroid refractory acute GVHD in pediatric pa-
tients, we retrospectively reviewed the charts of 12 patients (median
age 6.5years, range 1.25-21years) with grades II (n 5 1), III (n5 6),
or IV (n 5 5) steroid refractory acute GVHD who received alemtu-
zumab for treatment. Steroid refractory acute GVHDwas defined as
progression of GVHD after 48 hours of./5 2 mg/kg steroid treat-
ment, or lack of response within 5 days. Patients received a median
dose of 0.73mg/kg alemtuzumab (range 0.3-2mg/kg) divided over
2-5 days. Seventy-five percent of patients received repeated courses.
A complete response, defined asGVHDof grade 0 at 4 weeks follow-
ing the first alemtuzumab course, was observed in 7 patients (58%). A
partial response, defined as a grade improvement after 4 weeks, was
